Tarsons Products Limited
Tarsons Products Limited operates in Medical Equipment & Supplies, part of the Healthcare sector. It booked ₹110 cr of revenue in its latest quarter (Q1 FY27) and kept -1.3% of sales as profit. It is the 4th largest of 7 Medical Equipment & Supplies companies we track, by market value.
| Segment | FY25 | FY26 | Share |
|---|---|---|---|
| India | 314 | 333 | 80% → 79% |
| Germany | 78 | 90 | 20% → 21% |
| Intersegment Revenue-India | 0 | 0 | 0% → 0% |
| Rest of the World | 0 | 0 | 0% → 0% |
| Total | 392 | 423 |
From the company's consolidated segment filings (Ind AS 108). Margin is segment operating profit (before interest & tax) over segment revenue; reconciliation rows like inter-segment eliminations are excluded from the mix.
“Tarsons Products Limited (referred to as ‘TPL,’ ‘Tarsons,’ or ‘the Company’) is one of India’s leading labware manufacturers, engaged in the designing, development, manufacturing, and marketing of consumables, reusables, and benchtop equipment & instruments.”
“is to grow business and become the most valued Labware Company in the life science space through world-class performance, creating growing value for the Indian economy and the Company’s stakeholders.”
Healthier than 40% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 81–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 40
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
What if I invest in TARSONS?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹110 cr |
| Other Income | ₹6 cr |
| Total Income | ₹116 cr |
| Cost of Materials | ₹22 cr |
| Purchases of Stock-in-Trade | ₹13 cr |
| Inventory Change (±) | ₹4 cr |
| Employee Benefit Expense | ₹21 cr |
| Finance Costs | ₹6 cr |
| Depreciation & Amortisation | ₹27 cr |
| Other Expenses | ₹24 cr |
| Total Expenses | ₹118 cr |
| Profit before Tax | ₹-1 cr |
| Tax Expense | ₹12 L |
| Net Profit | ₹-1 cr |
| Net margin on total income | -1.2% |
The company made a net loss of ₹1 cr this quarter — income covered only ₹99 of every ₹100 it spent on costs and tax.
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 108 cr | 121 cr | 110 cr |
| Total income | 116 cr | 128 cr | 116 cr |
| Expenses | 107 cr | 122 cr | 118 cr |
| Profit before tax | 8 cr | 6 cr | -1 cr |
| Tax | 2 cr | 2 cr | 12 L |
| Net profit (owners' share) | 5 cr | 4 cr | -1 cr |
| Net margin (owners' share, on revenue) | 4.7% | 3.5% | -1.3% |
| EPS (₹) | 0.95 | 0.79 | -0.27 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Poly Medicure Limited | ₹1,713 | ₹17,360 cr | 50.4 | 11.1% | 16.4% | — |
| Molbio Diagnostics Limited | ₹1,285 | ₹14,493 cr | 61.7 | — | 14.4% | — |
| Fischer Medical Ventures Limited | ₹33 | ₹2,180 cr | 138.8 | 3.9% | 4.6% | — |
| Tarsons Products Limitedthis company | ₹308 | ₹1,638 cr | — | -0.9% | -1.3% | — |
| Laxmi Dental Limited | ₹198 | ₹1,089 cr | 26.5 | 16.9% | 13.8% | — |
| Fabtech Technologies Limited | ₹147 | ₹653 cr | 38.7 | 4.0% | 5.6% | — |
| Nureca Limited | ₹332 | ₹317 cr | 25.9 | 6.8% | 7.6% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹2 / share | 20 Sep 2024 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 4 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.